MedTrace Logo

Computerized Anger-Reduction Treatment for Smoking Cessation

NCT02413814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-01-28

No results posted yet for this study

Summary

Problematic anger is a strong predictor of failed attempts at smoking cessation. The investigators proposed study seeks to evaluate whether a novel 8-session computerized anger-reduction treatment improves quit rates among smokers. Smokers with elevated trait anger will be administered transdermal nicotine patch therapy and either anger-reduction treatment or a control intervention. They will be assessed throughout treatment and up until three months after a scheduled mid- treatment quit date. The investigators propose to test whether, compared to the control condition, the anger-reduction treatment will lead to: 1) greater reductions in anger and 2) greater abstinence rates at post-cessation and at follow-up assessments. The investigators will also test whether changes in anger-related symptoms account for group differences in abstinence rates.

Conditions

  • Anger
  • Smoking Cessation

Interventions

BEHAVIORAL

Anger Reduction Treatment

Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.

BEHAVIORAL

Control Condition

Eight 30-minute sessions of informative videos on healthy living and relaxation videos.

Sponsors & Collaborators

  • Florida State University

    lead OTHER

Principal Investigators

  • Jesse R Cougle, Ph.D. · Florida State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2019-07-30
Completion
2019-07-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413814 on ClinicalTrials.gov